These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 12894544)
1. Carcinomas unresponsive to either cisplatinum or anti-EGFR therapy can be growth inhibited by combination therapy of both agents. Knecht R; Peters S; Adunka O; Strebhardt K; Gstoettner W; Hambek M Anticancer Res; 2003; 23(3B):2577-83. PubMed ID: 12894544 [TBL] [Abstract][Full Text] [Related]
2. Tumor necrosis factor alpha sensitizes low epidermal growth factor receptor (EGFR)-expressing carcinomas for anti-EGFR therapy. Hambek M; Solbach C; Schnuerch HG; Roller M; Stegmueller M; Sterner-Kock A; Kiefer J; Knecht R Cancer Res; 2001 Feb; 61(3):1045-9. PubMed ID: 11221831 [TBL] [Abstract][Full Text] [Related]
3. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Perera RM; Narita Y; Furnari FB; Gan HK; Murone C; Ahlkvist M; Luwor RB; Burgess AW; Stockert E; Jungbluth AA; Old LJ; Cavenee WK; Scott AM; Johns TG Clin Cancer Res; 2005 Sep; 11(17):6390-9. PubMed ID: 16144944 [TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines. Hoffmann T; Hafner D; Ballo H; Haas I; Bier H Anticancer Res; 1997; 17(6D):4419-25. PubMed ID: 9494544 [TBL] [Abstract][Full Text] [Related]
5. Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model. Straughn JM; Oliver PG; Zhou T; Wang W; Alvarez RD; Grizzle WE; Buchsbaum DJ Gynecol Oncol; 2006 Apr; 101(1):46-54. PubMed ID: 16271751 [TBL] [Abstract][Full Text] [Related]
6. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466 [TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Luwor RB; Johns TG; Murone C; Huang HJ; Cavenee WK; Ritter G; Old LJ; Burgess AW; Scott AM Cancer Res; 2001 Jul; 61(14):5355-61. PubMed ID: 11454674 [TBL] [Abstract][Full Text] [Related]
8. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Fan Z; Baselga J; Masui H; Mendelsohn J Cancer Res; 1993 Oct; 53(19):4637-42. PubMed ID: 8402640 [TBL] [Abstract][Full Text] [Related]
9. Differentiation or immune destruction: two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor. Modjtahedi H; Eccles S; Sandle J; Box G; Titley J; Dean C Cancer Res; 1994 Apr; 54(7):1695-701. PubMed ID: 8137284 [TBL] [Abstract][Full Text] [Related]
10. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. Lammerts van Bueren JJ; Bleeker WK; Bøgh HO; Houtkamp M; Schuurman J; van de Winkel JG; Parren PW Cancer Res; 2006 Aug; 66(15):7630-8. PubMed ID: 16885363 [TBL] [Abstract][Full Text] [Related]
11. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin. Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592 [TBL] [Abstract][Full Text] [Related]
13. Antitumor effects of telomelysin in combination with paclitaxel or cisplatin on head and neck squamous cell carcinoma. Kondo N; Tsukuda M; Kimura M; Fujita K; Sakakibara A; Takahashi H; Ishiguro Y; Toth G; Matsuda H Oncol Rep; 2010 Feb; 23(2):355-63. PubMed ID: 20043095 [TBL] [Abstract][Full Text] [Related]
14. EGFR antibody-supplemented TPE-chemotherapy. Preclinical investigations to a novel approach for head and neck cancer induction treatment. Knecht R; Peters S; Solbach C; Baghi M; Gstöttner W; Hambek M Anticancer Res; 2003; 23(6C):4789-95. PubMed ID: 14981927 [TBL] [Abstract][Full Text] [Related]
15. Anti-tumor activity of monoclonal antibody CIBCNSH3 generated to the human EGF receptor. Udayachander M; Dean CJ; Meenakshi AN; Sivakumar N; Babu PB; Sivakumar J Hum Antibodies; 1997; 8(2):60-4. PubMed ID: 9289389 [TBL] [Abstract][Full Text] [Related]
16. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2. Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821 [TBL] [Abstract][Full Text] [Related]
17. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Klement G; Huang P; Mayer B; Green SK; Man S; Bohlen P; Hicklin D; Kerbel RS Clin Cancer Res; 2002 Jan; 8(1):221-32. PubMed ID: 11801563 [TBL] [Abstract][Full Text] [Related]
18. Combined administration of antibodies to human interleukin 8 and epidermal growth factor receptor results in increased antimetastatic effects on human breast carcinoma xenografts. Salcedo R; Martins-Green M; Gertz B; Oppenheim JJ; Murphy WJ Clin Cancer Res; 2002 Aug; 8(8):2655-65. PubMed ID: 12171898 [TBL] [Abstract][Full Text] [Related]
19. Cancer of the uterine cervix is susceptible to anti-EGF-R antibody EMD 55,900 therapy. Solbach C; Roller M; Nicolettri M; Budischewski K; Knecht R; Kaufmann M Anticancer Res; 2005; 25(6B):4261-7. PubMed ID: 16309226 [TBL] [Abstract][Full Text] [Related]
20. EGFR-antibody-supplemented TPF chemotherapy. Preclinical investigations to a novel approach for head and neck cancer induction treatment. Knecht R; Peters S; Hambek M; Solbach C; Baghi M; Gstöttner W; Hambek M Adv Otorhinolaryngol; 2005; 62():81-91. PubMed ID: 15608420 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]